cystamine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 19 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cystamine is beneficial to Huntington disease (HD) transgenic mice." | 7.73 | Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. ( Cooper, AJ; Hayden, MR; Jeitner, TM; Krasnikov, BF; Leavitt, BR; Pinto, JT; Thaler, HT; Van Raamsdonk, JM, 2005) |
| "Neurodegenerative disorders are a subset of disabling pathologies characterized, in part, by a progressive and specific loss of certain brain cell populations." | 6.47 | Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. ( Cicchetti, F; Gibrat, C, 2011) |
| "Cystamine treatment also ameliorated the striatal volume loss and striatal neuronal atrophy observed in these animals, but was unable to prevent motor dysfunction or the down-regulation of dopamine and cyclic adenosine monophsophate-regulated phosphoprotein (DARPP-32) expression in the striatum." | 5.33 | Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. ( Bailey, CD; Hayden, MR; Johnson, GV; Leavitt, BR; Pearson, J; Rogers, DA; Van Raamsdonk, JM, 2005) |
| "Cystamine is a candidate drug; however, the mechanisms by which it operates remain unclear." | 5.33 | Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. ( Alberch, J; Borrell-Pagès, M; Brouillet, E; Bryson, EA; Canals, JM; Cheetham, ME; Cordelières, FP; Grange, G; Guillermier, M; Hantraye, P; Hirsch, E; Humbert, S; Néri, C; Parker, JA; Pineda, JR; Saudou, F, 2006) |
| "Cystamine is beneficial to Huntington disease (HD) transgenic mice." | 3.73 | Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. ( Cooper, AJ; Hayden, MR; Jeitner, TM; Krasnikov, BF; Leavitt, BR; Pinto, JT; Thaler, HT; Van Raamsdonk, JM, 2005) |
| " Treatment in R6/2 transgenic HD mice, using the transglutaminase inhibitor cystamine, significantly extended survival, improved body weight and motor performance, and delayed the neuropathological sequela." | 3.71 | Therapeutic effects of cystamine in a murine model of Huntington's disease. ( Beal, MF; Bogdanov, M; Cooper, AJ; Dedeoglu, A; Ferrante, RJ; Hersch, SM; Jeitner, TM; Kowall, NW; Kubilus, JK; Matson, SA; Matson, WR; Ratan, RR, 2002) |
| "Neurodegenerative disorders are a subset of disabling pathologies characterized, in part, by a progressive and specific loss of certain brain cell populations." | 2.47 | Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. ( Cicchetti, F; Gibrat, C, 2011) |
| "Cystamine is a byproduct of pantetheinase-catalyzed pantothenic acid recycling from pantetheine for biosynthesis of Coenzyme A (CoA), a ubiquitous and metabolically indispensable cofactor." | 2.43 | Post-translational disulfide modifications in cell signaling--role of inter-protein, intra-protein, S-glutathionyl, and S-cysteaminyl disulfide modifications in signal transmission. ( Chu, F; O'Brian, CA, 2005) |
| "Cystamine treatment of various genetic models of HD demonstrated protection against neurodegeneration and/or improvement in behavior." | 1.37 | Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice. ( Leavitt, BR; Sivananthan, SN, 2011) |
| "Huntington's disease is a well-known genetic disorder associated with trinucleotide repeat expansions." | 1.37 | Therapeutic advances in the management of Huntington's disease. ( Abdulrahman, GO, 2011) |
| "Cystamine treatment also ameliorated the striatal volume loss and striatal neuronal atrophy observed in these animals, but was unable to prevent motor dysfunction or the down-regulation of dopamine and cyclic adenosine monophsophate-regulated phosphoprotein (DARPP-32) expression in the striatum." | 1.33 | Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. ( Bailey, CD; Hayden, MR; Johnson, GV; Leavitt, BR; Pearson, J; Rogers, DA; Van Raamsdonk, JM, 2005) |
| "Cystamine is a candidate drug; however, the mechanisms by which it operates remain unclear." | 1.33 | Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. ( Alberch, J; Borrell-Pagès, M; Brouillet, E; Bryson, EA; Canals, JM; Cheetham, ME; Cordelières, FP; Grange, G; Guillermier, M; Hantraye, P; Hirsch, E; Humbert, S; Néri, C; Parker, JA; Pineda, JR; Saudou, F, 2006) |
| "In parts of the brain affected by Huntington's disease, the amount of the huntingtin with expanded polyglutamine is reduced and there appear huntingtin-containing polymers of larger molecular weight." | 1.30 | Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. ( Djian, P; Green, H; Kahlem, P, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 13 (68.42) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ribeiro, M | 1 |
| Silva, AC | 1 |
| Rodrigues, J | 1 |
| Naia, L | 1 |
| Rego, AC | 1 |
| Bortvedt, SF | 1 |
| McLear, JA | 1 |
| Messer, A | 1 |
| Ahern-Rindell, AJ | 1 |
| Wolfgang, WJ | 1 |
| Gibrat, C | 1 |
| Cicchetti, F | 2 |
| Sivananthan, SN | 1 |
| Leavitt, BR | 3 |
| Abdulrahman, GO | 1 |
| Dedeoglu, A | 1 |
| Kubilus, JK | 1 |
| Jeitner, TM | 2 |
| Matson, SA | 1 |
| Bogdanov, M | 1 |
| Kowall, NW | 1 |
| Matson, WR | 1 |
| Cooper, AJ | 2 |
| Ratan, RR | 1 |
| Beal, MF | 1 |
| Hersch, SM | 2 |
| Ferrante, RJ | 3 |
| Lesort, M | 1 |
| Lee, M | 1 |
| Tucholski, J | 1 |
| Johnson, GV | 3 |
| Fox, JH | 1 |
| Barber, DS | 1 |
| Singh, B | 1 |
| Zucker, B | 1 |
| Swindell, MK | 1 |
| Norflus, F | 1 |
| Buzescu, R | 1 |
| Chopra, R | 1 |
| Kazantsev, A | 1 |
| Zainelli, GM | 1 |
| Dudek, NL | 1 |
| Ross, CA | 1 |
| Kim, SY | 1 |
| Muma, NA | 1 |
| Wang, X | 1 |
| Sarkar, A | 1 |
| Yu, M | 1 |
| Zhu, A | 1 |
| Jokivarsi, K | 1 |
| Saint-Pierre, M | 1 |
| Brownell, AL | 1 |
| Bailey, CD | 2 |
| Pinto, JT | 1 |
| Van Raamsdonk, JM | 2 |
| Hayden, MR | 2 |
| Thaler, HT | 1 |
| Krasnikov, BF | 1 |
| O'Brian, CA | 1 |
| Chu, F | 1 |
| Pearson, J | 1 |
| Rogers, DA | 1 |
| Borrell-Pagès, M | 1 |
| Canals, JM | 1 |
| Cordelières, FP | 1 |
| Parker, JA | 1 |
| Pineda, JR | 1 |
| Grange, G | 1 |
| Bryson, EA | 1 |
| Guillermier, M | 1 |
| Hirsch, E | 1 |
| Hantraye, P | 1 |
| Cheetham, ME | 1 |
| Néri, C | 1 |
| Alberch, J | 1 |
| Brouillet, E | 1 |
| Saudou, F | 1 |
| Humbert, S | 1 |
| Frankish, H | 1 |
| Ryu, H | 1 |
| Lee, J | 1 |
| Hagerty, SW | 1 |
| Soh, BY | 1 |
| McAlpin, SE | 1 |
| Cormier, KA | 1 |
| Smith, KM | 1 |
| Kahlem, P | 1 |
| Green, H | 1 |
| Djian, P | 1 |
| Karpuj, MV | 1 |
| Becher, MW | 1 |
| Springer, JE | 1 |
| Chabas, D | 1 |
| Youssef, S | 1 |
| Pedotti, R | 1 |
| Mitchell, D | 1 |
| Steinman, L | 1 |
2 reviews available for cystamine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
Topics: Animals; Cystamine; Cysteamine; Disease Models, Animal; Enzyme Inhibitors; Humans; Huntington Diseas | 2011 |
Post-translational disulfide modifications in cell signaling--role of inter-protein, intra-protein, S-glutathionyl, and S-cysteaminyl disulfide modifications in signal transmission.
Topics: Animals; Cystamine; Disulfides; Glutathione; Humans; Huntington Disease; Mice; Oxidation-Reduction; | 2005 |
17 other studies available for cystamine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Oxidizing effects of exogenous stressors in Huntington's disease knock-in striatal cells--protective effect of cystamine and creatine.
Topics: Corpus Striatum; Creatinine; Cystamine; Enzymes; Humans; Huntington Disease; Hydrogen Peroxide; Oxid | 2013 |
Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Antibodies; Cystamine; Disease Models, Animal; Drosophila me | 2010 |
Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice.
Topics: Animals; Corpus Striatum; Cystamine; Disease Models, Animal; Eicosapentaenoic Acid; Huntington Disea | 2011 |
Therapeutic advances in the management of Huntington's disease.
Topics: Cystamine; Humans; Huntington Disease; Peptides; Recombinant Fusion Proteins; RNA Interference; Sing | 2011 |
Therapeutic effects of cystamine in a murine model of Huntington's disease.
Topics: Administration, Oral; Aged; Animals; Behavior, Animal; Biomarkers; Body Weight; Caudate Nucleus; Cys | 2002 |
Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders.
Topics: Caspase 3; Caspase Inhibitors; Caspases; Cystamine; Cysteine Proteinase Inhibitors; Enzyme Activatio | 2003 |
Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.
Topics: Animals; Antioxidants; Brain; Buthionine Sulfoximine; Cystamine; Cysteine; Cytoprotection; Disease M | 2004 |
Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
Topics: Aged; Aged, 80 and over; Alternative Splicing; Brain; Calcium-Binding Proteins; Cell Line; Cell Surv | 2005 |
Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease.
Topics: Age Factors; Animals; Binding, Competitive; Body Weight; Brain; Brain Chemistry; Brain Mapping; Cere | 2005 |
The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase.
Topics: Age Factors; Age of Onset; Animals; Body Weight; Cystamine; Disease Models, Animal; Disease Progress | 2006 |
Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease.
Topics: Animals; Brain; Chromatography, High Pressure Liquid; Colorimetry; Cystamine; Cysteamine; Female; Gl | 2005 |
Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.
Topics: Administration, Oral; Animals; Corpus Striatum; Cystamine; Disease Models, Animal; Drug Administrati | 2005 |
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.
Topics: Aged; Animals; Brain; Brain-Derived Neurotrophic Factor; Caenorhabditis elegans; Cystamine; Cysteami | 2006 |
Drug shows potential for treatment of Huntington's disease.
Topics: Brain-Derived Neurotrophic Factor; Cell Death; Cystamine; Cysteamine; Enzyme Inhibitors; Humans; Hun | 2006 |
ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease.
Topics: Aged; Animals; Cystamine; Female; Gene Expression; Histone-Lysine N-Methyltransferase; Histones; Hum | 2006 |
Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine.
Topics: Adolescent; Adult; Age Factors; Cells, Cultured; Cerebral Cortex; Cystamine; Female; Humans; Hunting | 1998 |
Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.
Topics: Animals; Brain; Cystamine; Enzyme Inhibitors; Humans; Huntington Disease; Mice; Mice, Transgenic; Mo | 2002 |